Beta Bionics (NASDAQ:BBNX) Stock Bumped Up to Strong-Buy by Barclays

Barclays upgraded shares of Beta Bionics (NASDAQ:BBNX) to a strong-buy rating in a report released on Tuesday morning,Zacks reports.

Other analysts also recently issued research reports about the company. Wells Fargo & Company started coverage on Beta Bionics in a research note on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 target price on the stock. UBS Group restated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Tuesday, September 15th. Robert W. Baird increased their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. William Blair began coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, Bank of America boosted their target price on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $17.43 on Tuesday. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The company has a market capitalization of $784.18 million, a P/E ratio of -10.56 and a beta of 3.39. The company has a fifty day moving average of $18.66 and a 200 day moving average of $14.96.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million for the quarter. Analysts forecast that Beta Bionics will post -2.02 EPS for the current year.

Insiders Place Their Bets

In related news, insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the transaction, the insider directly owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. This trade represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christy Jones sold 6,430 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total value of $147,890.00. Following the sale, the director owned 19,564 shares in the company, valued at approximately $449,972. This trade represents a 24.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 97,697 shares of company stock worth $1,907,034. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Beta Bionics

Several hedge funds have recently modified their holdings of BBNX. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the second quarter worth $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Beta Bionics during the 4th quarter valued at about $40,437,000. Eversept Partners LP increased its holdings in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the period. 12 West Capital Management LP purchased a new position in shares of Beta Bionics in the fourth quarter worth about $17,520,000. Finally, Bruce & Co. Inc. purchased a new stake in Beta Bionics in the first quarter valued at approximately $5,518,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several law firms reminded shareholders that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. The notices primarily solicit potential claimants and do not represent a new operational development. Rosen Law Firm deadline notice
• Negative Sentiment: Multiple firms, including Hagens Berman, Kaplan Fox, Rosen and others, say the lawsuit alleges Beta Bionics and certain executives minimized the significance of an FDA Form 483 and failed to adequately disclose regulatory concerns involving iLet. The allegations reportedly include more than 18,000 unreported complaints and preceded an FDA Warning Letter becoming public. The claims have not been proven. Hagens Berman Beta Bionics class-action alert
• Negative Sentiment: The legal coverage highlights the severity of the prior selloff: BBNX allegedly fell from a Class Period high near $31.99 to below $9 across several FDA-related disclosures. The continuing stream of law-firm announcements increases headline, litigation and reputational risk, helping explain the stock’s decline and volatility. Levi and Korsinsky investor alert

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.